<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693574</url>
  </required_header>
  <id_info>
    <org_study_id>G1</org_study_id>
    <nct_id>NCT02693574</nct_id>
  </id_info>
  <brief_title>Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori</brief_title>
  <official_title>Comparison Efficacy of 14-day Triple Therapy Between Clarithromycin and Levofloxacin on the Eradication of Helicobacter Pylori in Syrian Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damascus Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UNIPHARMA. Universal Pharmaceutical Industries</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ibn Alhaytham Pharma. Industries Co</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Damascus Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison Efficacy of 14-day Triple Therapy between Clarithromycin and levofloxacin on the
      Eradication of Helicobacter Pylori in Syrian population
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2015</start_date>
  <completion_date type="Anticipated">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">January 28, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate according to Intention to treat (ITT) and per-protocol (PP) analysis</measure>
    <time_frame>6 weeks after eradication therapy</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Helicobacter Pylori Gastrointestinal Tract Infection</condition>
  <arm_group>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clarithromycin 500 mg Tablets and Esomeprazole 20 mg Capsule And Amoxicillin 1000 mg,Tablets by mouth every 12 hours for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levofloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levofloxacin 500 mg coated tablets and Esomeprazole 20 mg Capsule and Amoxicillin 1000 mg Tablets by mouth every 12 hours for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <arm_group_label>Clarithromycin</arm_group_label>
    <other_name>Esomeprazole</other_name>
    <other_name>Amoxicillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <arm_group_label>Levofloxacin</arm_group_label>
    <other_name>Esomeprazole,Amoxicillin</other_name>
    <other_name>Amoxicillin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1-Patients are aged greater than 18 years old who have H. pylori infection diagnosed by any
        of following three methods: I-Positive rapid urease test (CLOtest). II-Histologic evidence
        of H. pylori by modified Giemsa staining. III-Positive 13C-urea breath test. without prior
        eradication therapy and are willing to receive therapy.

        Exclusion Criteria:

          1. Children and teenagers aged less than 18 years.

          2. Previous eradication treatment for H. pylori.

          3. Patients who took any drug, which could influence the study results such as proton
             pump inhibitor, H2 blocker, mucosal protective agent and antibiotics.

          4. History of gastrectomy.

          5. Gastric malignancy, including adenocarcinoma and lymphoma,

          6. Previous allergic reaction to antibiotics (Amoxicillin, Clarithromycin, Levofloxacin)
             and prompt pump inhibitors (Es-omeprazole).

          7. Contraindication to treatment drugs.

          8. Pregnant or lactating women.

          9. Severe concurrent disease.

         10. Liver cirrhosis.

         11. Chronic kidney disease.

         12. Patients who cannot give informed consent by himself or herself.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Damascus Hospital</name>
      <address>
        <city>Damascus</city>
        <zip>+963</zip>
        <country>Syrian Arab Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Syrian Arab Republic</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>March 18, 2017</last_update_submitted>
  <last_update_submitted_qc>March 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Helicobacter Infections</keyword>
  <keyword>Proton Pump Inhibitors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 3, 2017</submitted>
    <returned>October 2, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

